Jemal A, Bray F, Center M, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
Slamon D, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 2001;344:783-92.
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014;32:3744-52.
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997- 4013.
Gullo G, Bettio D, Torri V, et al. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab- based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs 2008; 27:179-83.
Mansfield A, Sukov W, Eckel-Passow J, et al. Comparison of Fluorescence In Situ Hybridization (FISH) and Dual- ISH (DISH) in the Determination of HER2 Status in Breast Cancer. Am J Clin Pathol 2013;139:144-50.
Horii R, Matsuura M, Iwase T, et al. Comparison of dualcolor in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer. Breast Cancer 2014;21:598-604.
Wolff A, Hammond E, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol. 2009;17:1-7.
Shin SJ, Hyjek E, Early E, Knowles DM. Intratumoral heterogeneity of HER2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 2006;14:279-84.
Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/ CAP criteria. Am J Clin Pathol 2009;131:678-82.
Hanna WM, Rüschoff J, Bilous M, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 2014;27:4-18.
Shuangshoti S, Sawatdee R, Sakapibunnan A, et al. Heterogeneity of Unilateral Multiple Breast Cancer: Implications for Biomarker Testing. Bangkok Med J 2015;8:17-21.
Fuchs E, Köstler W, Horvat R, et al. High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting. Int J Cancer 2014;135:224-31.
